Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Page 1
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.
Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, Gahlemann M, James A, Kohlbrenner V, Alves M, Khanna D, Highland KB; SENSCIS-ON trial investigators. Allanore Y, et al. Among authors: azuma a. Ann Rheum Dis. 2022 Dec;81(12):1722-1729. doi: 10.1136/ard-2022-222564. Epub 2022 Aug 16. Ann Rheum Dis. 2022. PMID: 35973804 Free PMC article.
An open-label extension trial, SENSCIS-ON, is assessing safety and FVC decline during longer term nintedanib treatment. METHODS: Patients who completed the SENSCIS trial or a drug-drug interaction (DDI) study of nintedanib and oral contraceptive on treatment were eligible …
An open-label extension trial, SENSCIS-ON, is assessing safety and FVC decline during longer term nintedanib treatment. METHODS: Pati …
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.
Cottin V, Koschel D, Günther A, Albera C, Azuma A, Sköld CM, Tomassetti S, Hormel P, Stauffer JL, Strombom I, Kirchgaessler KU, Maher TM. Cottin V, et al. Among authors: azuma a. ERJ Open Res. 2018 Oct 19;4(4):00084-2018. doi: 10.1183/23120541.00084-2018. eCollection 2018 Oct. ERJ Open Res. 2018. PMID: 30364407 Free PMC article.
Idiopathic Pulmonary Fibrosis: Treatment and Prognosis.
Fujimoto H, Kobayashi T, Azuma A. Fujimoto H, et al. Among authors: azuma a. Clin Med Insights Circ Respir Pulm Med. 2016 Dec 8;9(Suppl 1):179-185. doi: 10.4137/CCRPM.S23321. eCollection 2015. Clin Med Insights Circ Respir Pulm Med. 2016. PMID: 27980445 Free PMC article. Review.
These drugs prevent deterioration but do not improve IPF. Therefore, nonpharmacologic approaches such as long-term oxygen therapy, pulmonary rehabilitation, and lung transplantation must be considered as additional treatment modalities....
These drugs prevent deterioration but do not improve IPF. Therefore, nonpharmacologic approaches such as long-term oxygen therapy, pu …
Long-term efficacy of macrolide treatment in idiopathic pulmonary fibrosis: a retrospective analysis.
Kuse N, Abe S, Hayashi H, Kamio K, Saito Y, Usuki J, Azuma A, Kudoh S, Gemma A. Kuse N, et al. Among authors: azuma a. Sarcoidosis Vasc Diffuse Lung Dis. 2016 Oct 7;33(3):242-246. Sarcoidosis Vasc Diffuse Lung Dis. 2016. PMID: 27758989
BACKGROUND AND OBJECTIVE: There is growing evidence for anti-inflammatory activities of macrolides in chronic respiratory diseases, such as diffuse panbronchiolitis, cystic fibrosis, or chronic bronchitis. The long-term effect of macrolides in idiopathic pulmonary fibrosis …
BACKGROUND AND OBJECTIVE: There is growing evidence for anti-inflammatory activities of macrolides in chronic respiratory diseases, such as …
Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis.
Bando M, Yamauchi H, Ogura T, Taniguchi H, Watanabe K, Azuma A, Homma S, Sugiyama Y; Japan Pirfenidone Clinical Study Group. Bando M, et al. Among authors: azuma a. Intern Med. 2016;55(5):443-8. doi: 10.2169/internalmedicine.55.5272. Epub 2016 Mar 1. Intern Med. 2016. PMID: 26935361 Free article.
OBJECTIVE: Long-term effects of pirfenidone have been poorly understood to date. This study investigated the clinical efficacy and safety of long-term pirfenidone use for idiopathic pulmonary fibrosis (IPF) in clinical practice. ...
OBJECTIVE: Long-term effects of pirfenidone have been poorly understood to date. This study investigated the clinical efficacy and sa …
Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.
Inomata M, Nishioka Y, Azuma A. Inomata M, et al. Among authors: azuma a. Core Evid. 2015 Aug 27;10:89-98. doi: 10.2147/CE.S82905. eCollection 2015. Core Evid. 2015. PMID: 26346347 Free PMC article. Review.
Combination therapy with nintedanib and pirfenidone is anticipated, although further evaluation of its long-term safety is needed. There is limited evidence for the safety of the combination therapy although a Phase II trial conducted in Japan demonstrated that combination …
Combination therapy with nintedanib and pirfenidone is anticipated, although further evaluation of its long-term safety is needed. Th …
Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease.
Miura Y, Saito T, Fujita K, Tsunoda Y, Tanaka T, Takoi H, Yatagai Y, Rin S, Sekine A, Hayashihara K, Nei T, Azuma A. Miura Y, et al. Among authors: azuma a. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):235-8. Sarcoidosis Vasc Diffuse Lung Dis. 2014. PMID: 25363224
Scleroderma-related interstitial lung disease has usually been treated with cyclophosphamide; however, its effect was evaluated to be modest and long-term administration of this drug is associated with adverse effects. ...
Scleroderma-related interstitial lung disease has usually been treated with cyclophosphamide; however, its effect was evaluated to be modest …
Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia - short term evaluation of safety and tolerability.
Kamio K, Azuma A, Ohta K, Sugiyama Y, Nukiwa T, Kudoh S, Mizushima T. Kamio K, et al. Among authors: azuma a. BMC Pulm Med. 2014 May 17;14:86. doi: 10.1186/1471-2466-14-86. BMC Pulm Med. 2014. PMID: 24886036 Free PMC article. Clinical Trial.
Considering the results of the current study, further investigations into the effects and treatment potential of long-term administration of lecithinized superoxide dismutase may be warranted. ...
Considering the results of the current study, further investigations into the effects and treatment potential of long-term administra …
Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events.
Sawada T, Takahashi T, Yamada H, Dahlöf B, Matsubara H; KYOTO HEART Study Group. Sawada T, et al. J Hum Hypertens. 2009 Mar;23(3):188-95. doi: 10.1038/jhh.2008.116. Epub 2008 Sep 18. J Hum Hypertens. 2009. PMID: 18800142 Clinical Trial.
It remains to be determined whether the evidence in Western countries for blockade of the renin-angiotensin System in cardiovascular diseases could be directly applied to East Asian races including the Japanese population as a long-term strategy. The KYOTO HEART Study (KHS …
It remains to be determined whether the evidence in Western countries for blockade of the renin-angiotensin System in cardiovascular disease …
EM703, a new derivative of erythromycin, inhibits transforming growth factor-beta signaling in human lung fibroblasts.
Yu C, Azuma A, Li Y, Wang C, Abe S, Usuki J, Matsuda K, Kudoh S, Sunazuka T, Omura S. Yu C, et al. Among authors: azuma a. Exp Lung Res. 2008 Aug;34(6):343-54. doi: 10.1080/01902140802093238. Exp Lung Res. 2008. PMID: 18600500
Long-term, low-dose macrolide therapy has been proven to improve survival in patients with diffuse panbronchiolitis and cystic fibrosis, although the mechanisms by which it does so remain unknown. ...
Long-term, low-dose macrolide therapy has been proven to improve survival in patients with diffuse panbronchiolitis and cystic fibros …
25 results